Pharmaceutics
from brain and spinal cord injury
Kelly L. Drew, phd
Prof. Drew serves in the Department of Chemistry and Biochemistry at the University of Alaska Fairbanks with over 70 peer-reviewed publications and 30 years experience in biomedical research focused on hibernation and brain injury.
Benjamin Mattes, Phd
Dr. Mattes is an established entrepreneur of small research and development companies, and former founder, CEO and President, Santa Fe Science and Technology.
Bernard W. Laughlin, DO
Clinician/Scientist leading preclinical studies.
Numerous student and graduate researchers are also participating on this development.
Kelly Seekatz
Why Invest?
Target Market
Business Model
BeCool Pharmaceutics is a small molecule drug development company, focused on creating therapeutics to modulate metabolism and body temperature by mimicking mechanisms used in hibernation.
BCP 190 and 191 follow a traditional drug development model.
Achievements
- Preclinical validation
- At IND enabling stage
- Continuing preclinical large and small animal efficacy studies
- ITHS early product development grant awarded
- M.J. Murdock Charitable Trust, Commercialization grant awarded
Kelly Drew
907.388.5311
kdrew@becoolpharma.com